NO973402L - Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger - Google Patents

Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger

Info

Publication number
NO973402L
NO973402L NO973402A NO973402A NO973402L NO 973402 L NO973402 L NO 973402L NO 973402 A NO973402 A NO 973402A NO 973402 A NO973402 A NO 973402A NO 973402 L NO973402 L NO 973402L
Authority
NO
Norway
Prior art keywords
therapy
analogs
aza
contraception
well
Prior art date
Application number
NO973402A
Other languages
English (en)
Norwegian (no)
Other versions
NO973402D0 (no
Inventor
John F W Keana
Sui Xiong Cai
Vladimir V Martin
Zhang-Lin Zhou
James M Navratil
Original Assignee
Oregon State
Acea Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State, Acea Pharm Inc filed Critical Oregon State
Publication of NO973402D0 publication Critical patent/NO973402D0/no
Publication of NO973402L publication Critical patent/NO973402L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO973402A 1995-01-27 1997-07-23 Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger NO973402L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37969995A 1995-01-27 1995-01-27
US08/466,043 US5801183A (en) 1995-01-27 1995-06-06 Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
PCT/US1995/016575 WO1996022990A2 (fr) 1995-01-27 1995-12-21 Analogues aza et aza (n-oxy) d'antagonistes de recepteurs n-methyle-d-aspartate (ndma) glycine

Publications (2)

Publication Number Publication Date
NO973402D0 NO973402D0 (no) 1997-07-23
NO973402L true NO973402L (no) 1997-09-17

Family

ID=27008733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973402A NO973402L (no) 1995-01-27 1997-07-23 Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger

Country Status (11)

Country Link
US (1) US5801183A (fr)
EP (1) EP0805809A2 (fr)
JP (1) JP2002515012A (fr)
KR (1) KR19980701668A (fr)
AU (1) AU718748B2 (fr)
BR (1) BR9510265A (fr)
CA (1) CA2211608A1 (fr)
FI (1) FI973047A7 (fr)
NO (1) NO973402L (fr)
NZ (1) NZ300778A (fr)
WO (1) WO1996022990A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307451A2 (fr) 2000-08-04 2003-05-07 Warner-Lambert Company Llc Procede de preparation de 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido 2,3-d]pyrymidin-7-ones
US20020187295A1 (en) * 2001-05-15 2002-12-12 Fuji Photo Film Co., Ltd. Magnetic transfer master medium
EP1467970B1 (fr) * 2002-01-17 2007-08-22 Merck & Co., Inc. Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
HUP0500200A2 (hu) * 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003265740B8 (en) * 2002-10-04 2010-06-03 Prana Biotechnology Limited Neurologically-active compounds
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
EP1648890A2 (fr) * 2003-07-18 2006-04-26 Basf Aktiengesellschaft Composes de 3-arylpyridine arylcondenses et leur utilisation pour lutter contre des champignons pathogenes
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
CN101534826A (zh) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
AU2007268749B2 (en) * 2006-05-26 2012-07-26 Taisho Pharmaceutical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
US8338337B2 (en) * 2008-10-29 2012-12-25 Basf Se Substituted pyridines having a herbicidal effect
BRPI1008214A2 (pt) 2009-06-05 2015-08-25 Basf Se "composto de pirazina da fórmula i, composto da fórmula i, processo para preparar o composto da fórmula i, composição e método para controlar uma vegetação indesejável"
BRPI1011784A2 (pt) * 2009-06-18 2016-03-22 Pfizer compostos bicíclicos e tricíclicos como inibidores de kat ii
WO2011117195A1 (fr) * 2010-03-23 2011-09-29 Basf Se Pyridines substituées ayant une action herbicide
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos
CN114369069B (zh) * 2022-01-21 2024-03-15 江苏丰山生化科技有限公司 一种精喹禾灵环合物中间体的制备方法
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1490998A (en) * 1975-09-23 1977-11-09 Beecham Group Ltd Nitronaphthylridine derivatives and pharmaceutical compositions comprising them
US4103257A (en) * 1976-05-25 1978-07-25 The United States Of America As Represented By The United States Department Of Energy Azaquinolone dye lasers
US4128649A (en) * 1977-06-29 1978-12-05 Sandoz, Inc. 4-Hydroxy-pyrido[2,3-b]pyridine-2(1H)-one-3-carboxylic acids and esters
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
US5268378A (en) * 1990-05-31 1993-12-07 Merck Sharp & Dohme, Limited Dioxo-tetrahydroquinoline derivatives
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
JPH04178385A (ja) * 1990-11-09 1992-06-25 Yamanouchi Pharmaceut Co Ltd ジケトピリドピラジン誘導体
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
AU9049391A (en) * 1990-12-20 1992-07-22 Warner-Lambert Company 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity
IL101860A0 (en) * 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
EP0647137B1 (fr) * 1992-06-22 2008-08-13 The Regents Of The University Of California Antagonistes des recepteurs de glycine et leur utilisation
TW274550B (fr) * 1992-09-26 1996-04-21 Hoechst Ag
US5622965A (en) * 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof

Also Published As

Publication number Publication date
AU4602496A (en) 1996-08-14
BR9510265A (pt) 1997-11-04
FI973047A7 (fi) 1997-08-28
WO1996022990A3 (fr) 1996-10-10
FI973047A0 (fi) 1997-07-18
KR19980701668A (ko) 1998-06-25
JP2002515012A (ja) 2002-05-21
NZ300778A (en) 1999-01-28
EP0805809A2 (fr) 1997-11-12
AU718748B2 (en) 2000-04-20
NO973402D0 (no) 1997-07-23
US5801183A (en) 1998-09-01
CA2211608A1 (fr) 1996-08-01
WO1996022990A2 (fr) 1996-08-01

Similar Documents

Publication Publication Date Title
NO973402L (no) Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger
AU2015237245B2 (en) Potent soluble epoxide hydrolase inhibitors
DE69334237D1 (de) Glycinrezeptorantagonisten und ihre verwendung
YU57599A (sh) Primena derivata fumarne kiseline
US6380220B1 (en) Derivatives from piperidine-keto acid, their preparation and use
TW201416340A (zh) Ａｔｘ調節劑
WO1995018616A3 (fr) 8-aza, 6-aza et 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones et leur utilisation comme antagonistes du recepteur de la glycine ou du nmda
TW201402537A (zh) 犬尿胺酸－３－單氧化酶抑制劑，其醫藥組成物及使用方法
DK0495982T3 (da) Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
KR20180100453A (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
NO934501L (no) Karboksylsyrederivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
MXPA05009524A (es) Derivados de imidazol-4-il-etinil-piridina.
HRP20000776A2 (en) New substituted amides, their production and their use
EP0664289A3 (fr) Isoquinoléines
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
CA2793138C (fr) Sels d'hydroxybenzoate de composes de metanicotine
IE902849A1 (en) Novel compounds
GR3031901T3 (en) Substituted pyrroles.
CN109983012A (zh) 赖氨酸牙龈蛋白酶的酮抑制剂
JO2260B1 (en) Piperidine ethanesulfonyl derivatives
TW201418198A (zh) 轉麩醯胺酸酶ｔｇ２抑制劑，醫藥組成物及其使用方法
El Oualid et al. Design, Synthesis, and Evaluation of Su-gar Amino Acid Based Inhibitors of Pro-tein Prenyl Transferases PFT and PGGT-1
CA2360326A1 (fr) Utilisation de 4-amino pyridine pour le traitement de neuropathies peripheriques
EP1270007A3 (fr) Microemulsions pour l'administration cutanee d'apomorphine pour le traitement de la maladie de Parkinson
US6787564B2 (en) Optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application